Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors

British Journal of Cancer

Volumn 108, Issue 12, 2013, Pages 2478-2484

  Kaymakcalan, M D ^a   Je, Y ^b   Sonpavde, G ^c   Galsky, M ^d   Nguyen, P L ^a,e   Heng, D Y C ^f   Richards, C J ^g   Choueiri, T K ^g  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Kyung Hee University   (South Korea)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f TOM BAKER CANCER CENTRE   (Canada)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; EXEMESTANE; LETROZOLE; OCTREOTIDE; PLACEBO; SUNITINIB; TEMSIROLIMUS;

ARTICLE; ASPERGILLOSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANDIDIASIS; COMPARATIVE STUDY; GASTROINTESTINAL INFECTION; HEPATITIS C; HERPES SIMPLEX; HUMAN; INFECTION; KIDNEY CARCINOMA; META ANALYSIS; MYCOSIS; PARASITOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RISK FACTOR; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT INFECTION; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INFECTION; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84879691105     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.278     Document Type: Article

References (40)

1. Abraham RT, Gibbons JJ (2007) The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13: 3109-3114.
2. Ansell SM, Inwards DJ, Rowland Jr KM, Flynn PJ, Morton RF, Moore Jr DF, Kaufmann SH, Ghobrial I, Kurtin PJ, Maurer M, Allmer C, Witzig TE (2008) Low-dose, single temsirolimus for relapsed mantle cell lymphoma. Cancer 113(3): 508-514.
3. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmound T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2012) Everolimus in postmenopausal hormone-receptro-positive advanced breast cancer. N Engl J Med 366: 520-529.
4. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27: 2630-2637.
5. Beaumont J, Butt Z, Baladi J, Motzer RJ, Haas T, Hollaender N, Kay A, Cella D (2011) Patient-reported outcomes in a phase III study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. Oncologist 16: 632-640.
6. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
7. Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, Dorner A, Immermann F, Burczynski ME (2005) Population pharmacokinetics of CCI-779: correlation to safety and pharmacogenomic responses in patients with advanced renal cell. Clin Pharmacol Ther 77(1): 76-89.
8. Budde K, Kingswood C, Zonnenberg B, Frost M, Belousova E, Sauter M, Fischerder M, Nonomura N, ebin M, Pei Y, Brakemeier S, Sahmoud T, Shah G, Lincy J, Bissler J (2012) Everolimus in the treatment of angiolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleimymatosis: results from EXIST-2. Presented at 27th Annual European Association of Urology Congress, 24-28 February (2012) Paris, France.
9. Calvo E, Escudier B, Motzer R, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Ravaud A, Kim D, Panneerselvam A, Anak O, Figlin RA (2011) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48: 333-339.
10. Chapman TM, Perry CM (2004) Everolimus. Drugs 64(8): 861-872.
11. Choueiri TK, Je Y, Sonpavde G, Richards CJ, Galsky MD, Nguyen PL, Schutz F, Heng DY, Kaymakcalan M (2013) Incidence and risk of treatment related mortality in cancer patients treated with mammalian target of rapamycin inhibitor. Ann Oncol; e-pub ahead of print 8 May 2013; doi:10.1093/annonc/ mdt155.
12. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10: 101-129.
13. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
14. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
15. Elsen T, Sternberg CN, Robert C, Mulders P, Zbinden S, Izzedine H, Escudier B (2012) Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 104: 93-113.
16. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 23: 5294-5304.
17. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B (2009) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27: 3822-3829.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
19. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
20. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ (2008) Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13: 1084-1096.
21. Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17: 1-12.
22. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363: 1801-1811.
23. Lai JH, Tan TH (1994) CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin. J Biol Chem 269(48): 30077-30080.
24. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62: 1006-1012.
25. Motzer R, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer 116: 4256-4465.
26. Motzer R, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 372: 449-456.
27. Nashan B (2002) Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 11(12): 1845-1857.
28. Negrier S, Gravis G, Perol D, Chevreau C, Delva R, Bay JO, Blanc E, Geoffrois L, Rolland F, Legouffe E, Sevin E, Laguerre B, Escudier B (2011) Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomized phase 2 trial. Lancet Oncol 12(7): 673-680.
29. Novartis (2012) Afinitor (everolimus) Package Insert. Novartis Pharma Stein AG: Stein, Switzerland.
30. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Custem E, Yao JC (2011) Everolimus plus octreotide long-active repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378: 2005-2012.
31. Pfizer Inc (2012) Torisel (temsirolimus) Package Insert. Pfizer Inc: Philadelphia, PA.
32. Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ (2011) Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 47(9): 1287-1298.
33. Ravaud A (2011) Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 16(suppl 2): 32-44.
34. Sakaria JN, Galanis E, Wu W, Dietz AB, Kaufmann TJ, Gustafson MP, Brown PD, Uhm JH, Rao RD, Doyle L, Giannini C, Jaeckle KA, Buckner JC (2010) Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res 16: 5573-5580.
35. Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH (1997) SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64: 36-42.
36. Shegal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35(suppl 3): 7S-14S.
37. Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, Belani CP, Argiris A (2010) Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 16(23): 5900-5907.
38. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127.
39. Tsukamoto T, Shinohara N, Tsuchiya N, Hamamoto Y, Maruoka M, Fujimoto H, Niwakawa M, Uemura H, Usami M, Terai A, Kanayama HO, Sumiyoshi Y, Eto M, Akaza H (2011) Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of japanese patients from RECORD-1. J Clin Oncol 41: 17-24.
40. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 346: 514-523.